Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol

European Journal of Haematology

Volumn 63, Issue 2, 1999, Pages 86-93

  Gaiger, A ^a   Linnerth, B ^a   Mann, G ^b   Schmid, D ^a   Heinze, G ^a   Tisljar, K ^a   Haas, O A ^b   Gadner, H ^b   Lion, T ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

Author keywords

Childhood acute lymphocytic leukaemia; PCR; Prognostic factors; Wilms' tumour gene

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE; MERCAPTOPURINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; BLAST CELL; BONE MARROW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOPHENOTYPING; INFANT; KARYOTYPE; LEUKOCYTE COUNT; MALE; NEPHROBLASTOMA; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SKULL IRRADIATION; TUMOR SUPPRESSOR GENE;

EID: 0032795913     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1999.tb01121.x     Document Type: Article

References (44)

1. 1. GRUEMAYER ER, GADNER H, MUTZ I, et al. Childhood acute lymphoblastic leukemia: Results of the Austrian cooperative study group with the ALL A 84 protocol. Medical and Paediatric Oncology 1990;18:6-14.
2. 2. SCHRAPPE M, REITER A, SAUTER S, et al. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukaemia in children and adolescents: the significance of initial therapy response in blood and bone marrow]. Klin-Padiatr 1994;206:208-211.
3. 3. REITER A, SCHRAPPE M, LUDWIG WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-3133.
4. 4. CONTER V, SCHRAPPE M, ARICO M, et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin Frankfurt-Munster groups. J Clin Oncol 1997;15:2786-2791.
5. 5. BOWTRAVAHI R, LEAVITT P, SALLAN SE, et al. New directions of St.Jude total-therapy protocols: Study X for standard-risk childhood acute lymphoblastic leukemia. In: MURPHY SB, GILBERT JR, eds. Leukemia Research. New York: Elsevier Biomedical, 1983.
6. 6. MIWA H, BERAN M, SAUNDERS GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 1992;6:405-409.
7. 7. MENSSEN HD, RENKL HJ, RODECK U, MAURER J, NOTTER M, SCHWARTZ S. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 1995;9:1060-1067.
8. 8. ALGAR E, BLACKBURN D, KROMYKII T, TAYLOR G, SMITH P. Mutation analysis of the WT1 gene in sporadic childhood acute lymphocytic leukemias. Leukemia 1997;11:110-113.
9. 9. INOUE K, SUGIYAMA H, OGAWA H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-3077.
10. 10. CARAPETI M, GOLDMAN JM, CROSS NC. Dominant-negative mutations of the Wilms' tumour predisposing gene (WT1) are infrequent in CML blast crisis and de novo acute leukaemia. Eur J Haematol 1997;58:346-349.
11. 11. MENSSEN HD, RENKL HJ, RODECK U, et al. Detection by monoclonal antibodies of the Wilms' tumor (WT1) nuclear protein in patients with acute leukemia. Int J Cancer 1997;70:518-523.
12. 12. MATSUNGA E. Genetics of Wilms' tumor. Hum Genet 1981;57:231-246.
13. 13. COPPES MJ, WILLIAMS BRG. The molecular genetics of Wilms tumor. Cancer Investigation 1994;12:57-65.
14. 14. ROSE EA, GLASER T, JONES C, et al. Complete physical map of the WAGR region of 11p13 localizes a candidate Wilms' tumor gene. Cell 1990;60:495-508.
15. 15. CALL KM, GLASER T, ITO CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumour locus. Cell 1990;60:509-520.
16. 16. RODECK U, BOSSLER A, KARI C, et al. Expression of the wt1 Wilms' tumor gene by normal and malignant human melanocytes. Int J Cancer 1994;59:78-82.
17. 17. WALKER C, RUTTEN F, YUAN X, et al. Wilms' tumor suppressor gene expression in rat and human mesothelioma. Cancer Res 1994;62:3101-3106.
18. 18. LANGERAK AW, WILLIAMSON KA, MIYAGAWA K, et al. Expression of the Wilms' tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression. Genes. Chromosomes Cancer 1995;12:87-96.
19. 19. VIEL A, GIANNINI F, CAPOZZI E, et al. Molecular mechanisms possibly affecting WT1 function in human ovarian tumors. Int J Cancer 1994;57:515-521.
20. 20. TELEMAN A, DODEMONI H, DEGRAEF C, et al. Identification of the cellular protein encoded by the human Wilms' tumour (WT1) gene. Oncogene 1992;7:2545-2548.
21. 21. HABER DA, SOHN RL, BUCKLER AJ, PELLFTTER J, CALL KM, HOUSMAN DE. Alternative splicing and genomic structure of the Wilms tumor gene WT1. Proc Natl Acad Sci USA 1991;88:9618-9622.
22. 22. RAUSCHER III FJJ, MORRIS JF, TOURNAY OE, COOK DM, CURRAN T. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science 1990;250:1259-1262.
23. 23. DRUMMOND IA, MADDEN SL, ROHWER P, BELL GI, SUKHATME VP, RAUSCHER III FJ. Repression of the insulin-like growth factor gene by the Wills' tumor suppressor WT1. Science 1992;257:674-678.
24. 24. FRAIZER GC, PATMASIRIWAT P, ZHANG X, SAUNDERS GF. Expression of the tumor suppressor gene WT1 in both human and mouse bone marrow. Blood 1995;86:4704-4706.
25. 25. BAIRD PN, SIMMONS PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997;25:312-320.
26. 26. MENSSEN HD, RENKL HJ, ENTEZAMI M, THIEL E. Wilms' tumor gene expression in human CD34+ hematopoietic progenitors during fetal development and early clonogenic growth. Blood 1997;89:3486-3487.
27. 27. INOUE K, OGAWA H, SONODA Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405-1412.
28. 28. YAMAGAMI T, SUGIYAMA H, INOUE K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: Implications for the involvement of WT1 in leukemogenesis. Blood 1996;87:2878-2884.
29. 29. ALGAR EM, KHROMYKH T, SMITH SI, BLACKBURN DM, BRYSON GJ, SMITH PJ. A WT1 antisense oligonucleotidc inhibits proliferation and induces apoptosis in myeloid leukemia cell lines. Oncogene 1996;12:1005-1014.
30. 30. GAIGER A, LION T, KALHS P, et al. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT). Leukemia 1993;11: 1766-1772.
31. 31. GAIGER A, HENN T, HOERTH E, et al. Increase of BCR-ABL chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia preceding disease progression. Blood 1995;86:2371-2378.
32. 32. BRENNER B, WILDHARDT G, SCHNEIDER S, ROYER-POKORA B. RNA polymerase chain reaction detects different levels of four alternatively spliced WT1 transcripts in Wilms' tumor. Oncogene 1992;7:1431-1433.
33. 33. SCHMID D, HEINZE G, LINNERTH B, et al. Prognostic significance of WT1 gene expression at diagnosis in adult de novo acute myeloid leukemia. Leukemia 1997;11:639-643.
34. 34. GAIGER A, SCHMID D, HEINZE G, et al. Detection of the WT1 transcript by RT-PCR in complete remission has no prognostic relevance in de novo acute myeloid leukemia. Leukemia 1998;12:1886-1894.
35. 35. LION T, IZRAELI S, HENN T, GAIGER A, MOR W, GADNER H. Monitoring of residual disease in chronic myelogenous leukemia by quantitative polymerase chain reaction. Leukemia 1992;6:495-499.
36. 36. LION T, HENN T, GAIGER A, KALHS P, GADNER H. Early detection of relapse after bone marrow transplantation in patients with chronic myelogenous leukaemia. Lancet 1993;341:275-276.
37. 37. HAAS OA, HINTERBERGER W, SCHMIDMEIER W, et al. Cytogenetic studies in bone marrow transplant recipients. Blut 1986;53:29-38.
38. 38. LION T, GAIGER A, HENN T, et al. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferone. Leukemia 1995;9:1353-1360.
39. 39. KAPLAN EM, MEIER P. Nonparametric estimation from incomplete observations. J Am Slat Assoc 1958;53:457-481.
40. 40. MANTEL N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports 1966;50:163-170.
41. 41. BRESLOW ME. A generalized Kruskal-Wallis Test for comparing K-samples subject to integral patterns of censorship. Biometrika 1970;57:579-594.
42. 42. WATZINGER F, LION T. Multiplex PCR for quality control of template RNA/cDNA in RT-PCR assays. Leukemia 1998;12;1894-1986.
43. 43. LION T, KIDD V. Debate Round Table: Appropriate controls for RT-PCR. Leukemia 1998;12:1983-1993.
44. 44. STOCK W, SHER D, DODGE R, et al. High levels of Wilms tumor gene expression is detected in the majority of newly diagnosed acute lymphoblastic leukemia (ALL) of adults: Implications for prognosis and monitoring of minimal residual disease (MRD). Blood 1998;92:223a (abstract).